ArticleThe oncologist2019
Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 5 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Progression-free survival prediction and comparative metastasis detection accuracy ofEuropean journal of nuclear medicine and molecular imaging · 2026Pooled it
- Head-to-Head comparison of [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- 18F-fluoroestradiol positron emission tomography in patients with breast cancer: a systematic review and meta-analysis.Revista da Associacao Medica Brasileira (1992) · 2023Pooled it
- Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.Frontiers in medicine · 2022Pooled it
- Pooled it
- Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art.EJNMMI radiopharmacy and chemistry · 2026Review
- Response-adaptive breast cancer care in the grey zones: integrating ER and HER2 targeted PET, FDG PET/CT under immunotherapy, and ctDNA kinetics.Exploration of targeted anti-tumor therapy · 2026Review
- Article
- Hybrid [AJNR. American journal of neuroradiology · 2025Article
- The role of dual-tracer PET imaging with ER and HER2 in patients with metastatic breast cancer: a pilot study.Annals of nuclear medicine · 2025Article
- Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives.Clinical and translational science · 2025Article
- Novel molecular imaging approaches in oncology: towards a more accurate estimation of tumour response.Current opinion in oncology · 2025Review
- The Role of [Cancers · 2025Review
- [EJNMMI research · 2025Article
- Utility ofProceedings (Baylor University. Medical Center) · 2024Article
- Does F-18 FDG-PET/CT Have an Additional Impact on Axillary Approach in Early-Stage Breast Cancer?European journal of breast health · 2024Article
- Head-to-head comparison ofEuropean journal of hybrid imaging · 2023Article
- Utility of positron emission tomography for determination of axillary metastasis of breast cancer.Turkish journal of surgery · 2023Article
- Article
- Advances in PET/CT Imaging for Breast Cancer.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe compared the clinical value of 16a-18F-fluoro-17b-estradiol ( MATERIALS AND
methodsWe retrospectively analyzed 19 female patients newly diagnosed with immunohistochemistry-confirmed estrogen receptor (ER)-positive breast cancer who underwent
resultsIn total, 238 lesions were analyzed in 19 patients with newly diagnosed ER-positive breast cancer. Lesion detection was achieved in 216 sites with
conclusionPerforming IMPLICATIONS FOR PRACTICE: This study investigated whether 16a-18F-fluoro-17b-estradiol (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.